Pentagon Orders Annual T Tests — NEW DETAILS

Five armed soldiers silhouetted against sunset background. — MILITARY BOMBSHELL

The Pentagon just turned testosterone into an annual readiness metric for every service member 30 and older.

Story Snapshot

A new Defense Department memo orders annual testosterone screening at age 30+ as part of the Periodic Health Assessment.
Leaders frame it as health and performance optimization tied to readiness.
Major medical guidance warns against blanket screening of asymptomatic men.
Doctors question benefits, cost, and risks of overtreatment from mass testing.

What the order does and who it covers

The Defense Department has added testosterone screening to the annual Periodic Health Assessment for all Active Duty and Reserve Component troops aged 30 and older.

The directive took effect with a signed memorandum that labels the testing a mandatory element of the assessment.

The policy sets screening as standard but does not force treatment decisions. Defense reporters and network outlets confirmed the requirement and its link to the readiness mission emphasized by leadership.

The US Pentagon issued detailed guidance for a new, mandatory testosterone deficiency screening policy for active-duty and reserve service members age 30 and older, a follow-up ‌to Defense Secretary Pete Hegseth's July announcement https://t.co/uJh0d2pFAQ

— Reuters (@Reuters) September 3, 2026

Commanders now have a new data point on medical readiness for a large slice of the force. The Pentagon’s message is clear: find possible testosterone deficiency, refer for evaluation, and offer therapy when appropriate.

Officials tie this to keeping troops sharp, resilient, and deployable. That framing aligns with the broader push to harden the force against preventable performance drains and to treat hormone deficiency like any other fixable medical limiter.

Why the medical debate is fierce

Specialty guidance has long drawn a bright line: confirm low levels and symptoms first, then consider therapy; do not screen the general population.

The Endocrine Society and the American Urological Association base that on evidence that lab values alone do not equal disease, levels vary by time of day, and mislabeling normal variation can cause harm.

Reporters found urologists and endocrinologists warning that blanket testing risks false positives, cascades of follow-up tests, and unneeded drugs.

Reuters highlighted that most experts they contacted saw no strong proof that screening every healthy 30-year-old improves combat readiness. Several warned the plan could lead to unnecessary or harmful treatment.

One clinician noted that benefits seen in clinics come from symptomatic men, not asymptomatic screen-detected cases. CBS echoed concerns about cost-effectiveness, logistics of proper morning, fasting draws, and the risk that therapy could reduce fertility or enlarge the prostate.

Readiness math, common sense, and guardrails

Readiness arguments land when the policy is targeted, measurable, and tied to outcomes troops care about: fewer injuries, faster recovery, sharper focus. Broad hormone screening can help identify real deficiency in men who would not speak up.

But common sense says mass testing must not shove people toward pills they do not need. The fix is not hard: make symptoms the gate.

Require confirmatory morning tests before any diagnosis. Publish clear referral rules that screen in high-risk groups and screen out healthy outliers.

Track outcomes that matter to units: ruck times, injury rates, heat illness, and deployment readiness. Report those numbers, not just lab counts.

If the Pentagon shows that careful case-finding cuts downtime and avoids overtreatment, the program will earn trust. If not, scale it back to targeted testing.

How service members should navigate the change

Troops should treat the test like any other readiness screen: show up rested, morning draw if possible, and ask for repeat confirmation if a value is low. Demand a conversation about symptoms and goals before any prescription.

Men planning families should ask about fertility risks. Women in uniform should ask how the policy affects them and what criteria apply. Medics and commanders should protect privacy and make clear that a lab value will not drive promotions or special duty status on its own.

Bottom line for the force

The order is real, sweeping, and anchored in a readiness pitch from the top. The clinical pushback is specific, not political: avoid mass screening of healthy people, confirm abnormalities, and treat only when symptoms and tests match.

The smart path threads both truths. Use the screen to find real disease. Build tight guardrails to stop mission creep and waste. Then publish the results so the ranks, Congress, and taxpayers can see whether this new metric pulls its weight.